Clinical trial NCT03150888: Multi-provincial Cohort for Hypertension (MUCH)
Official title: Multi-provincial Cohort for Hypertension in China
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hypertension
Lead sponsor: Beijing Institute of Heart, Lung and Blood Vessel Diseases
Sponsor class: OTHER
Collaborators: name: Beijing Tsinghua Chang Gung Hospital
name: Beijing Tiantan Hospital
name: Ruijin Hospital
name: Nanfang Hospital, Southern Medical University
name: Southwest Hospital, China
First posted: 2017-05-12
Enrollment: 30000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: primary care clinic, and community sample

Brief summary: The purpose of this study is to construct hypertension specialized cohort using uniform standards and specifications. This study timely collected multi-dimensional clinical information through electronic medical records, mobile health, data integration, informatics and computer modern techniques, linking self-reported data and big data platforms from different sources to timely obtain the incidence and mortality data, and integrating hypertension cohort samples and the associated clinical records systematically, in order to build a 30-thousand hypertension specialized cohort with fine phenotypic data and blood/urine samples, thus far to provide support for the development of precise medicine research and related industries.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of hypertension
* over 18 years old
* ti sign the informed consent

Exclusion Criteria:

* with life-threatening severe disease, such as severe tumor or AIDs
* pregnancy or lactating women,or plan to pregnant within half a year,
* with severe mental disorders
* participating in clinical trials

Primary outcomes:
measure: Composite end point of major cardiovascular and cerebrovascular events
timeFrame: From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
Secondary outcomes:
measure: New-onset of cardiovascular events
timeFrame: From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
measure: New-onset of stroke
timeFrame: From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
measure: Total death
timeFrame: From date of enrollment until date of death from all cause, assessed up to 3 year
measure: Major bleeding
timeFrame: From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
measure: Atrial fibrillation
timeFrame: From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Anzhen Hospital
city: Beijing
country: China
facility: Beijing Tiantan Hospital
city: Beijing
country: China
facility: Beijing Tsinghua Chang Gung Hospital
city: Chongqing
country: China
facility: Southwest Hospital, China
city: Guangzhou
country: China
facility: Nanfang Hospital of Southern Medical University
city: Shanghai
country: China
facility: Ruijin Hospital
Study officials:
affiliation: Beijing Institute of Heart, Lung and Blood Vessel Diseases
name: Jing Liu, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References: